Prostate Cancer Clinical Trial

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Summary

The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants with mCRPC who have failed to respond to either abiraterone acetate or enzalutamide (but not both) and to chemotherapy.

The primary study hypotheses are that the combination of pembrolizumab plus olaparib is superior to abiraterone acetate or enzalutamide with respect to:

Overall Survival (OS) and
Radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 as assessed by blinded independent central review (BICR)

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
Has prostate cancer progression while receiving androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before screening
Has current evidence of metastatic disease documented by bone lesions on bone scan and/or soft tissue disease shown by computed tomography/magnetic resonance imaging (CT/MRI)

Has received prior treatment with abiraterone acetate OR enzalutamide, but not both

Have disease that progressed during or after treatment with abiraterone acetate for either metastatic hormone-sensitive prostate cancer (mHSPC) or mCRP or enzalutamide for mCRPC for at least 8 weeks (at least 14 weeks for participants with bone progression)
Participants that received abiraterone acetate for mHSPC may not have received abiraterone acetate or enzalutamide for mCRPC
Have received docetaxel chemotherapy regimen for mCRPC and have had progressive disease during or after treatment with docetaxel
Has ongoing androgen deprivation with serum testosterone <50 ngdL (<2.0 nM)
If receiving bone resorptive therapy, including but not limited to bisphosphonates or denosumab, must have been receiving stable doses before randomization
Must agree to refrain from donating sperm during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention PLUS be abstinent from heterosexual intercourse OR must agree to use contraception unless confirmed to be azoospermic
Contraception use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirement above, the local label requirements are to be followed.
Has provided tumor tissue from a fresh core or excisional biopsy (obtained within 12 months of screening) from soft tissue not previously irradiated. Samples from tumors progressing at a prior site of radiation are allowed. Participants with bone-only or bone-predominant disease may provide a bone biopsy sample
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization

Exclusion Criteria:

Has a known additional malignancy that is progressing or has required active treatment in the last 3 years
Has an active autoimmune disease that has required systemic treatment in the past 2 years
Has a history of (noninfectious) pneumonitis requiring steroids, or has current pneumonitis
Has known active human immunodeficiency virus (HIV), hepatitis B virus (e.g., hepatitis B surface antigen reactive) or hepatitis C virus (HCV) infection (e.g., HCV RNA [qualitative] is detected)
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has a history of seizure or any condition that may predispose to seizure
Has a history of loss of consciousness within 12 months of screening
Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
Has (≥Grade 3) hypersensitivity to pembrolizumab and/or any of its excipients
Has known hypersensitivity to the components or excipients in olaparib, abiraterone acetate, prednisone or prednisolone, or enzalutamide
Has symptomatic congestive heart failure (New York Heart Association Class III or IV heart disease)
Has received an anticancer monoclonal antibody (mAb) before randomization
Has received prior treatment with olaparib or any other PARP inhibitor
Has received prior treatment with apalutamide or darolutamide
Has received prior treatment with enzalutamide or apalutamide for metastatic hormone-sensitive prostate cancer
Has used herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA (e.g., saw palmetto) before the date of randomization
Has received prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer
Has received prior treatment with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, or CD137)
Is currently receiving either strong or moderate inhibitors of cytochrome P450 [CYP] (CYP3A4) that cannot be discontinued for the duration of the study
Has received a previous allogenic bone marrow transplant or double umbilical cord transplantation (dUCBT) or a solid organ transplant
Has received a live vaccine within 30 days prior to the date of randomization
Is currently participating in or has participated in a study of an investigational agent, or has used an investigational device, within 4 weeks before the date of randomization
Has a bone "superscan"
Is expecting to father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study intervention

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

793

Study ID:

NCT03834519

Recruitment Status:

Active, not recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 190 Locations for this study

See Locations Near You

St. Joseph Heritage Healthcare ( Site 0069)
Fullerton California, 92835, United States
UCLA Hematology/Oncology - Santa Monica ( Site 0081)
Los Angeles California, 90404, United States
Sibley Memorial Hospital ( Site 0096)
Washington District of Columbia, 20016, United States
Georgia Cancer Center at Augusta University ( Site 0026)
Augusta Georgia, 30912, United States
Quincy Medical Group ( Site 0021)
Quincy Illinois, 62301, United States
Tulane Cancer Center ( Site 0066)
New Orleans Louisiana, 70112, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0005)
Baltimore Maryland, 21287, United States
Chesapeake Urology Research Associates ( Site 0076)
Towson Maryland, 21204, United States
Beth Israel Deaconess Medical Ctr. ( Site 0093)
Boston Massachusetts, 02215, United States
Dana Farber Cancer Institute ( Site 0033)
Boston Massachusetts, 02215, United States
UMass Memorial Medical Center ( Site 0053)
Worcester Massachusetts, 01655, United States
Barbara Ann Karmanos Cancer Institute ( Site 0077)
Detroit Michigan, 48201, United States
Henry Ford Health System ( Site 0039)
Detroit Michigan, 48202, United States
St. Vincent Frontier Cancer Center ( Site 0016)
Billings Montana, 59102, United States
Nebraska Cancer Specialists ( Site 0034)
Omaha Nebraska, 68130, United States
Comprehensive Cancer Centers of Nevada ( Site 0092)
Las Vegas Nevada, 89169, United States
University of New Mexico Cancer Center ( Site 0048)
Albuquerque New Mexico, 87131, United States
Memorial Medical Center ( Site 0095)
Las Cruces New Mexico, 88011, United States
Associated Medical Professionals of NY ( Site 0060)
Syracuse New York, 13210, United States
Duke Cancer Center Cary ( Site 0010)
Cary North Carolina, 27511, United States
Gabrail Cancer Center-Research ( Site 0097)
Canton Ohio, 44718, United States
The Urology Group- Cincinnati ( Site 0094)
Cincinnati Ohio, 45212, United States
University Hospitals of Cleveland Seidman Cancer Center ( Site 0036)
Cleveland Ohio, 44106, United States
Carolina Urologic Research Center ( Site 0070)
Myrtle Beach South Carolina, 29572, United States
Huntsman Cancer Institute ( Site 0002)
Salt Lake City Utah, 84112, United States
Virginia Cancer Institute ( Site 0052)
Richmond Virginia, 23230, United States
Blue Ridge Cancer Care ( Site 0086)
Roanoke Virginia, 24014, United States
Seattle Cancer Care Alliance ( Site 0079)
Seattle Washington, 98109, United States
Froedtert and Medical College of Wisconsin ( Site 0045)
Milwaukee Wisconsin, 53226, United States
Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)
Berazategui Buenos Aires, B1884, Argentina
Centro de Diagnostico Urologico ( Site 1008)
Buenos Aires Caba, C1120, Argentina
Hospital Britanico de Buenos Aires ( Site 1006)
Buenos Aires Caba, C1280, Argentina
Sanatorio Parque ( Site 1002)
Rosario Santa Fe, S2000, Argentina
Instituto de Investigaciones Metabolicas ( Site 1011)
Buenos Aires , C1012, Argentina
Hospital Aleman ( Site 1004)
Buenos Aires , C1118, Argentina
Instituto Medico Alexander Fleming ( Site 1010)
Buenos Aires , C1426, Argentina
CEMAIC ( Site 1014)
Cordoba , X5008, Argentina
St. Vincent's Hospital ( Site 0158)
Darlinghurst New South Wales, 2010, Australia
Macquarie University ( Site 0151)
Macquarie University New South Wales, 2109, Australia
Port Macquarie Base Hospital ( Site 0153)
Port Macquarie New South Wales, 2444, Australia
Calvary Mater Newcastle ( Site 0148)
Waratah New South Wales, 2298, Australia
Southern Medical Day Care Centre ( Site 0160)
Wollongong New South Wales, 2500, Australia
Royal Brisbane and Women s Hospital ( Site 0155)
Herston Queensland, 4029, Australia
John Flynn Hospital & Medical Centre ( Site 0164)
Tugun Queensland, 4224, Australia
Box Hill Hospital ( Site 0146)
Box Hill Victoria, 3128, Australia
Peter MacCallum Cancer Centre ( Site 0152)
Melbourne Victoria, 3000, Australia
Fiona Stanley Hospital ( Site 0162)
Murdoch Western Australia, 6150, Australia
Ordensklinikum Linz GmbH Elisabethinen ( Site 0373)
Linz Oberosterreich, 4020, Austria
Medizinische Universitat Graz ( Site 0374)
Graz Steiermark, 8036, Austria
SCRI-CCCIT GesmbH ( Site 0371)
Salzburg , 5020, Austria
Medizinische Universitaet Wien ( Site 0375)
Wien , 1090, Austria
Hospital de Caridade de Ijui ( Site 1038)
Ijui Rio Grande Do Sul, 98700, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021)
Porto Alegre Rio Grande Do Sul, 90610, Brazil
Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035)
Itajai Santa Catarina, 88301, Brazil
Hospital de Base de Sao Jose de Rio Preto ( Site 1022)
Sao Jose do Rio Preto Sao Paulo, 15090, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer ( Site 1040)
São Paulo Sao Paulo, 04014, Brazil
A.C. Camargo Cancer Center ( Site 1026)
Sao Paulo , 01509, Brazil
Cross Cancer Institute ( Site 0110)
Edmonton Alberta, T6G 1, Canada
BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0113)
Kelowna British Columbia, V1Y 5, Canada
BC Cancer-Vancouver Center ( Site 0112)
Vancouver British Columbia, V5Z 4, Canada
Nova Scotia Health Authority QEII-HSC ( Site 0114)
Halifax Nova Scotia, B3H 2, Canada
William Osler Health System (Brampton Civic Hospital) ( Site 0121)
Brampton Ontario, L6R 3, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0116)
Hamilton Ontario, L8V 5, Canada
Princess Margaret Cancer Centre ( Site 0107)
Toronto Ontario, M5G 2, Canada
CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102)
Rimouski Quebec, G5L 5, Canada
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105)
Sherbrooke Quebec, J1H 5, Canada
CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0103)
Quebec , G1R 2, Canada
Centro Investigación del Cáncer James Lind ( Site 1041)
Temuco Araucania, 47800, Chile
Rey y Oreilly Limitada ( Site 1048)
Temuco Araucania, 48101, Chile
Fundacion Arturo Lopez Perez ( Site 1049)
Santiago Region M. De Santiago, 75009, Chile
Pontificia Universidad Catolica de Chile ( Site 1047)
Santiago Region M. De Santiago, 83300, Chile
Bradford Hill Centro de Investigaciones Clinicas ( Site 1044)
Santiago Region M. De Santiago, 84203, Chile
C.H. de Saint Quentin ( Site 0481)
Saint Quentin Aisne, 02321, France
Clinique Sainte Anne ( Site 0431)
Strasbourg Alsace, 67000, France
Centre Jean Perrin ( Site 0434)
Clermont-Ferrand Auvergne, 63011, France
Institut Paoli Calmettes ( Site 0419)
Marseille Bouches-du-Rhone, 13009, France
CHU de Brest -Site Hopital Morvan ( Site 0441)
Brest Bretagne, 29200, France
CHU Jean Minjoz ( Site 0423)
Besancon Doubs, 25000, France
Institut Bergonie ( Site 0421)
Bordeaux Gironde, 33076, France
Institut Claudius Regaud IUCT Oncopole ( Site 0418)
Toulouse Haute-Garonne, 31059, France
Hopital Foch ( Site 0428)
Suresnes Hauts-de-Seine, 92150, France
Institut Regional du Cancer de Montpellier - ICM ( Site 0443)
Montpellier Herault, 34298, France
Institut De Cancerologie De L Ouest ( Site 0448)
Saint Herblain Loire-Atlantique, 44805, France
Centre Hospitalier Regional du Orleans ( Site 0430)
Orleans Loiret, 45100, France
Centre D Oncologie de Gentilly ( Site 0432)
Nancy Meurthe-et-Moselle, 54100, France
Centre Leon Berard ( Site 0422)
Lyon Rhone, 69373, France
C.H.U. Lyon Sud ( Site 0436)
Pierre Benite Rhone, 69310, France
CHU Amiens Picardie Site Sud Amiens ( Site 0438)
Amiens Somme, 80000, France
Institut Gustave Roussy ( Site 0416)
Villejuif Val-de-Marne, 94800, France
Institut Sainte Catherine ( Site 0447)
Avignon Vaucluse, 84000, France
Institut Mutualiste Montsouris ( Site 0446)
Paris , 75014, France
Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304)
Freiburg Baden-Wurttemberg, 79106, Germany
Universitaetsklinikum in Mannheim ( Site 0314)
Mannheim Baden-Wurttemberg, 68167, Germany
Studienpraxis Urologie ( Site 0309)
Nuertingen Baden-Wurttemberg, 72622, Germany
Universitaetsklinik fuer Urologie ( Site 0307)
Tuebingen Baden-Wurttemberg, 72076, Germany
Universitaetsklinikum Erlangen ( Site 0303)
Erlangen Bayern, 91054, Germany
Klinikum Rechts der Isar ( Site 0300)
Muenchen Bayern, 81675, Germany
Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318)
Nuernberg Bayern, 90419, Germany
Universitaetsklinikum Duesseldorf ( Site 0306)
Duesseldorf Nordrhein-Westfalen, 40225, Germany
Krankenhaus der Barmherzigen Brueder Trier ( Site 0310)
Trier Rheinland-Pfalz, 54292, Germany
Universitaetsklinikum Jena ( Site 0305)
Jena Thuringen, 07747, Germany
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0301)
Berlin , 10117, Germany
Tallaght University Hospital ( Site 0730)
Dublin , D24 N, Ireland
Mid Western Cancer Centre ( Site 0728)
Limerick , , Ireland
Ha Emek Medical Center ( Site 0548)
Afula , 18341, Israel
Assaf Harofe ( Site 0547)
Be'er- Ya'akov , 70300, Israel
Soroka Medical Center ( Site 0549)
Beer Sheva , 84101, Israel
Rambam Medical Center ( Site 0543)
Haifa , 31096, Israel
Hadassah Ein Kerem Medical Center ( Site 0546)
Jerusalem , 91120, Israel
Meir Medical Center ( Site 0544)
Kfar Saba , 44281, Israel
Rabin Medical Center ( Site 0545)
Petach-Tikwa , 49414, Israel
Chaim Sheba Medical Center ( Site 0541)
Ramat Gan , 52620, Israel
Sourasky Medical Center ( Site 0542)
Tel-Aviv , 64239, Israel
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0462)
Meldola Emilia-Romagna, 47014, Italy
Istituto Clinico Humanitas Research Hospital ( Site 0452)
Rozzano Lombardia, 20089, Italy
Medical Oncology Ospedale San Donato ( Site 0461)
Arezzo , 52100, Italy
Policlinico S.Orsola-Malpighi ( Site 0453)
Bologna , 40138, Italy
Azienda Ospedaliera Cannizzaro ( Site 0458)
Catania , 95126, Italy
Azienda Ospedaliera San Camillo Forlanini ( Site 0455)
Roma , 00152, Italy
Fondazione Policlinico Universitario A. Gemelli ( Site 0463)
Roma , 00168, Italy
Azienda Ospedaliera Santa Maria Terni ( Site 0456)
Terni , 05100, Italy
Presidio Ospedaliero Santa Chiara ( Site 0451)
Trento , 38122, Italy
Fujita Health University Hospital ( Site 0724)
Toyoake Aichi, 470-1, Japan
National Cancer Center Hospital East ( Site 0702)
Kashiwa Chiba, 277-8, Japan
Toho University Sakura Medical Center ( Site 0703)
Sakura Chiba, 285-8, Japan
National Hospital Organization Shikoku Cancer Center ( Site 0716)
Matsuyama Ehime, 791-0, Japan
Kobe City Medical Center General Hospital ( Site 0726)
Kobe Hyogo, 650-0, Japan
Kanazawa University Hospital ( Site 0701)
Kanazawa Ishikawa, 920-8, Japan
Kitasato University Hospital ( Site 0705)
Sagamihara Kanagawa, 252-0, Japan
Yokohama City University Medical Center ( Site 0706)
Yokohama Kanagawa, 232-0, Japan
Nara Medical University Hospital ( Site 0715)
Kashihara Nara, 634-8, Japan
Kindai University Hospital ( Site 0714)
Osakasayama Osaka, 589-8, Japan
Osaka University Hospital ( Site 0713)
Suita Osaka, 565-0, Japan
Saitama Medical University International Medical Center ( Site 0708)
Hidaka Saitama, 350-1, Japan
Dokkyo Medical University Saitama Medical Center ( Site 0707)
Koshigaya Saitama, 343-8, Japan
Fuji City General Hospital ( Site 0725)
Fuji Shizuoka, 417-8, Japan
Hamamatsu University Hospital ( Site 0720)
Hamamatsu Shizuoka, 431-3, Japan
Yamaguchi University Hospital ( Site 0717)
Ube Yamaguchi, 755-8, Japan
Chiba Cancer Center ( Site 0704)
Chiba , 260-8, Japan
Kyushu University Hospital ( Site 0718)
Fukuoka , 812-8, Japan
University of Miyazaki Hospital ( Site 0721)
Miyazaki , 889-1, Japan
Nagano Municipal Hospital ( Site 0723)
Nagano , 381-8, Japan
Nagasaki University Hospital ( Site 0719)
Nagasaki , 852-8, Japan
Osaka International Cancer Institute ( Site 0722)
Osaka , 541-8, Japan
Toranomon Hospital ( Site 0711)
Tokyo , 105-8, Japan
Nippon Medical School Hospital ( Site 0709)
Tokyo , 113-8, Japan
Keio University Hospital ( Site 0710)
Tokyo , 160-8, Japan
Chonnam National University Hwasun Hospital ( Site 0174)
Hwasun Gun Jeonranamdo, 58128, Korea, Republic of
National Cancer Center ( Site 0176)
Goyang-si Kyonggi-do, 10408, Korea, Republic of
Asan Medical Center ( Site 0171)
Songpagu Seoul, 05505, Korea, Republic of
Severance Hospital Yonsei University Health System ( Site 0173)
Seoul , 03722, Korea, Republic of
Samsung Medical Center ( Site 0172)
Seoul , 06351, Korea, Republic of
Medisch Centrum Leeuwarden ( Site 0477)
Leeuwarden Fryslan, 8934 , Netherlands
Radboud University Medical Center ( Site 0470)
Nijmegen Gelderland, 6525 , Netherlands
Antoni van Leeuwenhoek Ziekenhuis ( Site 0480)
Amsterdam Noord-Holland, 1066 , Netherlands
Vrije Universiteit Medisch Centrum ( Site 0479)
Amsterdam Noord-Holland, 1081 , Netherlands
Spaarne Ziekenhuis ( Site 0473)
Hoofddorp Noord-Holland, 2134 , Netherlands
Ziekenhuisgroep Twente ( Site 0469)
Hengelo Overijssel, 7555 , Netherlands
Haaglanden MC - locatie Antoniushove ( Site 0471)
Leidschendam Zuid-Holland, 2262 , Netherlands
Erasmus MC ( Site 0475)
Rotterdam Zuid-Holland, 3015 , Netherlands
Franciscus Gasthuis en Vlietland ( Site 0489)
Schiedam Zuid-Holland, 3118 , Netherlands
Auckland City Hospital ( Site 0193)
Auckland , 1023, New Zealand
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565)
Chelyabinsk Chelyabinskaya Oblast, 45408, Russian Federation
Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585)
Krasnoyarsk Krasnoyarskiy Kray, 66013, Russian Federation
Russian Scientific Center of Roentgenoradiology ( Site 0559)
Moscow Moskva, 11799, Russian Federation
Central Clinical Hospital with Polyclinic ( Site 0562)
Moscow Moskva, 12135, Russian Federation
Omsk Clinical Oncology Dispensary ( Site 0568)
Omsk Omskaya Oblast, 64401, Russian Federation
SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576)
Samara Samarskaya Oblast, 44303, Russian Federation
SBHI Leningrad Regional Oncology Dispensary ( Site 0588)
Saint Petersburg Sankt-Peterburg, 19110, Russian Federation
Clinical Research Center of specialized types medical care-Oncology ( Site 0570)
Saint Petersburg Sankt-Peterburg, 19775, Russian Federation
Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567)
Saint Petersburg Sankt-Peterburg, 19775, Russian Federation
Tomsk National Scientific Medical Center of Russian Academy of Science ( Site 0579)
Tomsk Tomskaya Oblast, 63402, Russian Federation
Instituto Catalan de Oncologia - ICO ( Site 0330)
L Hospitalet De Llobregat Barcelona, 08908, Spain
Hospital Parc Tauli ( Site 0335)
Sabadell Barcelona, 08208, Spain
Hospital San Pedro de Alcantara ( Site 0326)
Caceres Extremadura, 10003, Spain
Hospital Josep Trueta ( Site 0321)
Girona Gerona, 17007, Spain
Hospital Quiron Madrid ( Site 0325)
Pozuelo de Alarcon Madrid, 28223, Spain
Hospital del Mar ( Site 0333)
Barcelona , 08003, Spain
Hospital General Universitari Vall d Hebron ( Site 0334)
Barcelona , 08035, Spain
Hospital Clinic ( Site 0323)
Barcelona , 08036, Spain
Hospital Universitario Virgen de la Victoria ( Site 0337)
Malaga , 29016, Spain
National Cheng Kung University Hospital ( Site 0134)
Tainen Tainan, 704, Taiwan
China Medical University Hospital ( Site 0132)
Taichung , 40447, Taiwan
Taichung Veterans General Hospital ( Site 0133)
Taichung , 407, Taiwan
National Taiwan University Hospital ( Site 0131)
Taipei , 10048, Taiwan
Taipei Veterans General Hospital ( Site 0135)
Taipei , 11217, Taiwan
University Hospitals Bristol NHS Foundation Trust ( Site 0530)
Bristol Bristol, City Of, BS2 8, United Kingdom
Cambridge University Hospitals NHS Trust ( Site 0540)
Cambridge Cambridgeshire, CB2 0, United Kingdom
Torbay Hospital ( Site 0532)
Torquay Devon, TQ2 7, United Kingdom
Royal Marsden Hospital ( Site 0526)
Sutton England, SM2 5, United Kingdom
Musgrove Park Hospital ( Site 0537)
Taunton England, TA1 5, United Kingdom
University of North Midlands NHS Foundation Trust ( Site 0527)
Stoke-on-Trent Staffordshire, ST4 6, United Kingdom
Mount Vernon Cancer Centre ( Site 0536)
Northwood , HA6 2, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

793

Study ID:

NCT03834519

Recruitment Status:

Active, not recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.